Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis

Maurizio Cutolo

VITAMIN D: A TRUE ENDOGENOUS IMMUNOMODULATOR

Recently, vitamin D has received increased worldwide attention for its involvement in reducing risk for several chronic diseases including many cancers, infectious diseases, type 1 diabetes and notably autoimmune rheumatic diseases. The final active metabolite of vitamin D (1,25(OH)D) is considered a steroid hormone for its origin from cholesterol (D-hormone), and like glucocorticoids exerts immunomodulatory activities (figure 1). Pathophysiological investigations confirm that severe hypovitaminosis D, in genetically predisposed subjects, can impair self tolerance and immune responses by compromising the regulation of dendritic cells, regulatory T-lymphocytes (T regs), Th1 cells and B cell function.

Cross-sectional studies have shown that deficient serum levels of vitamin D (25(OH)D) (<20 ng/ml) are present in a significant percentage, not only in patients with autoimmune diseases such as multiple sclerosis (MS), type 1 diabetes, systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA), but also in healthy subjects. In addition, the presence of severe 25(OH)D deficiency (<10 ng/ml) is also involved in the generation of symptoms that characterise patients with rheumatic diseases (ie, musculoskeletal pain in RA), and supplementation seems to induce improvements.

VITAMIN D DEFICIENCY, AUTOANTIBODY INDUCTION AND IDIOPATHIC INFLAMMATORY MYOPATHIES

Azali et al report significant vitamin D deficiency in patients with idiopathic inflammatory myopathies (IIM)—polymyositis, dermatomyositis (DM), inclusion body myositis—compared to a gender matched control population and based on samples collected during the same months of the year. The IIM patients with shorter disease duration showed lower levels of serum 25(OH)D than those with established treated disease, supporting the hypothesis that low levels of vitamin D could be at least one of several risk factors in development of IIM, as already assessed in MS, RA and SLE.

The suggested role for low serum 25(OH)D as a risk factor in autoimmunity seems strongly reinforced by some recent investigations showing that even antinuclear antibodies (ANA)-positive healthy controls are significantly more likely to be deficient in vitamin D serum levels than ANA-negative healthy controls. Conversely, in a recent survey, vitamin D supplementation (140 000 IU at baseline and after 4 weeks) was found to be associated with significant increases of Tregs frequency (%Tregs) in apparently healthy individuals.

Interestingly, a significantly higher frequency of autoantibodies (anti-Jo-1) was also found by Azali et al in IIM patients who had significantly lower median serum 25(OH)D levels compared to controls. In addition to the finding that vitamin D deficiency is associated in SLE patients with certain immune abnormalities and significantly correlates in a negative manner with clinical SLE activity and anti-dsDNA titre, it is strongly suggested that vitamin D deficiency plays an important role in enhancing autoantibody production.

Interestingly, in an interventional study evaluating the immunological effects of vitamin D supplementation in 20 SLE patients with hypovitaminosis D, a decrease of memory B cells and anti-DNA antibodies together with a preferential increase of naive CD4 T cells, an increase of regulatory T cells and a decrease of effector Th1 and Th17 cells were observed. Furthermore, a very recent study showed that reduced serum 25(OH)D levels are associated with the presence of autoimmune response in tuberculosis patients, by reporting a significant negative correlation between the titres of the ANA and the serum levels of 25(OH)D.

A new and intriguing study links low serum 25(OH)D and elevated immunoreactivity against Epstein–Barr virus (EBV) in 25 individuals who had donated blood prior to the first clinical MS manifestation (clinically isolated syndrome). In fact, a novel role for low vitamin D as risk factor and/or modifier of autoimmune response is introduced. It is proposed that deprivation of solar light or low serum 25(OH)D at higher latitudes, facilitates the development of autoimmune diseases by aggravating the CD8 T-cell deficiency, thereby further impairing control of EBV and permitting clonal expansion of autoreactive B cells infected with EBV.

A LESSON FROM VITAMIN D AND CHRONIC INFECTIONS/INFLAMMATION: THE CASE OF TUBERCULOSIS

Vitamin D is synthesised at an increased rate inside monocytes/macrophages in the presence of bacterial and viral infections, and in normal conditions stimulates the synthesis of antimicrobial peptides such as cathelicidins, which contribute to bacterial killing and defence against pathogens (such as Mycobacterium tuberculosis).

These mechanisms support the beneficial therapeutic effects exerted by graded solar light exposure, which was used to treat chronic tuberculosis in the so called ‘sanatoria’ at the beginning of the twentieth century.

In addition, a systematic review of the period between 1971 and 2006 in 11 countries and regions from around the world confirmed a seasonal pattern for tuberculosis, with the most prominent peak during the winter and spring seasons (the time of the circannual reduction in vitamin D synthesis) in all of the countries studied.

Recently, 95 patients receiving antimicrobial therapy for pulmonary tuberculosis who were randomised to receive adjunctive high-dose vitamin D or placebo in a clinical trial, and who fulfilled criteria for per-
Figure 1  Newly identified target genes for calcitriol (D hormone) reveal multiple molecular pathways of anti-inflammatory actions for 1,25(OH)2D3 in several cell types. These include: inhibition of prostaglandin (PG) synthesis and biological actions; inhibition of p38 stress kinase activation and production of proinflammatory cytokines such as IL-6 (via induction of MAP kinase phosphatase 5 (MKP5) expression); inhibition of nuclear factor κB (NF-κB) signalling which results in the attenuation of the synthesis of proinflammatory cytokines such as interleukin-8 (IL-8) (via up-regulation of the expression of insulin-like growth factor binding protein-3 (IGFFBP-3); inhibition of angiogenesis due to suppressive effects on the expression of proangiogenic factors such as hypoxia-inducible factor 1 (HIF-1) and vascular endothelial growth factor; increase in the expression of E-cadherin, leading to the inhibition of invasion and metastasis. Solid lines indicate direct actions of calcitriol, and dotted lines indicate downstream effects of calcitriol.

Protocol analysis, also showed an accelerated resolution of inflammatory responses during tuberculosis treatment.16

The administration of vitamin D enhanced the treatment-induced suppression of antigen-stimulated Th1 cytokine responses and is a further lesson on the previously unrecognised anti-inflammatory activities exerted by 1,25(OH)2D3.

SOLAR LIGHT, VITAMIN D AVAILABILITY AND RA RISK

Linked to the different seasonal vitamin D availability, recent studies have shown that people living at the highest latitudes have a higher risk of RA, especially in winter, which may be due to lower ultraviolet (UV) light exposure.19 20 In fact, the UV light may suppress autoimmunity and thus may decrease the risk of RA. The very recent study by Arkema et al, investigating the association between UV-B light exposure and risk of RA among women in two large prospective cohort studies (the Nurses’ Health Study (NHS) and the NHSII) confirmed a significant decreased RA risk with higher UV-B exposure, in particular in the absence of sun-protective behaviours.21

Interestingly, 1514 incident RA cases were identified in total and among NHS participants, higher cumulative average UV-B exposure was associated with decreased RA risk; those in the highest versus lowest category had a 21% decreased RA risk (HR 0.79, 95%CI 0.66 to 0.94).

These results confirm the conclusions of another recent large cohort study, which showed that besides the usual initial biomarkers that have been associated with the progression of early RA, the season of symptom onset (ie, winter or spring) acts as an independent predictive factor for the progression of joint structural damage at 6 months.22 Furthermore, the onset of symptoms of early RA during winter or spring was also associated with greater radiographic evidence of disease progression at 12 months.23

Adding weight to these findings, multivariate analysis produced the same results in two adjoining seasons (winter and spring, summer and autumn), and at both 6 and 12 months, suggesting a clear role for solar light/vitamin D implication.22 25

On the other hand, if infections represent one of the risk factors (trigger factors) for the development of early RA (and generally autoimmune diseases), the seasonality of the onset and severity of RA might also be linked to the seasonality of infections and associated vitamin D deficiency, as previously discussed.24

Accordingly, abnormally large seasonal declines in vitamin D status (deficiency) may also trigger flares in patients with SLE.25 A recent investigation in non-Afro-American SLE patients showed that unusually large declines in vitamin D during low daylight months (October–March) may be mechanistically related to SLE flare, whereas relatively high vitamin D levels during high daylight months (July–August) may protect against flares.25

As mentioned above, vitamin D supplementation in SLE patients with hypovitaminosis D induced a decrease of memory B cells and anti-DNA antibodies, together with a preferential increase of naïve CD4 T cells, an increase of regulatory T cells and a decrease of effector Th1 and Th17 cells.11

Interestingly, a recent clinical study assessed that a significant solar-induced Δ25(OH)D was present at the earliest on 8 April, maximal by early August and decreased by late August, following the availability of efficient UV light doses.26

All this clinical and epidemiological evidence seems in agreement with several experimental studies, showing that UV radiation acts as an immunosuppressant by up-regulating Th2 cells, down-regulating Th1 cells, and inducing the production of interleukin-10 and T regulatory cells.27 28 UV-B exposure (solar light) could thus decrease the risk of RA onset as well as relapses, through increasing serum vitamin D, which exerts known immunomodulatory effects.29

April 2013 Vol 72 No 4
EMERGENT EVIDENCE: VITAMIN D DEFICIENCY AND AROMATASES IN RA AND CANCER

A prominent endocrine role for 1,25(OH)2D3 was recently discovered in peripheral oestrogen metabolism and in oestrogen-related cell proliferative activities. 1,25(OH)2D3 decreases the expression of aromatase, the enzyme that generally catalyses the peripheral synthesis of oestrogens from androgens, especially in cancer tissues where its intra-crine activity is significantly increased, such as in breast and prostate cancer.30

Similar inhibitory effects by 1,25(OH)2D3 have been recently reported on cultures of human macrophages with consequent reduced synthesis of cytokines.31 32

Inflammatory cytokines (tumour necrosis factor-α, interleukins 6 and 1) are strong enhancers of oestrogen activity, as observed in chronic inflammatory conditions such as RA synovitis or SLE skin.33 34 As a consequence, oestrogen metabolite synthesis is increased in synovial fluids of both male and female RA patients and seem involved in synovial cell proliferation.35

Interestingly, 1,25(OH)2D3 exerts an inhibitory effect by a direct repression of aromatase transcription via promoter II, as well as an indirect effect due to a reduction in the levels and biological activity of prostaglandins (especially PGE2), which are a major stimulator of aromatase transcription through promoter II.36

Aromatase inhibitors used in breast cancer treatment inhibit the enzymatic activity, while 1,25(OH)2D3 reduces aromatase expression. Recently, an enhanced growth inhibitory effect by combining 1,25(OH)2D3 and aromatase inhibitors in breast cancer cell cultures was revealed.37

The higher incidence of autoimmune rheumatic diseases in women also seems supported by possible links between vitamin D deficiency (with reduced down-regulation of aromatases), increased synthesis of peripheral oestrogens and increased risk/severity for RA, as already proposed in different types of cancer.37 38

CONCLUSIONS

Evidence supports an increased risk for autoimmune diseases, as well as for infections and cancer, in vitamin D deficiency. In the presence of overt disease, the severity of the process seems related to vitamin D deficiency. The link between the seasonality of 1,25(OH)2D3 deficiency and the circannual incidence and severity of at least some autoimmune rheumatic disorders, might be reduced by its thera-peutic supplementation.

Competing interests None.

Provenance and peer review Commissioned; externally peer reviewed.

Correction notice This paper has been corrected since it was published Online First. A new version of Figure 1 has replaced a previous incorrect version.

Received 27 October 2012
Accepted 1 January 2013

REFERENCES

Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis
Maurizio Cutolo

Ann Rheum Dis 2013 72: 473-475
doi: 10.1136/annrheumdis-2012-202538

Updated information and services can be found at:
http://ard.bmj.com/content/72/4/473

These include:
References
This article cites 38 articles, 10 of which you can access for free at:
http://ard.bmj.com/content/72/4/473#BIBL
Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
- Connective tissue disease (4253)
- Musculoskeletal syndromes (4951)
- Immunology (including allergy) (5144)
- Muscle disease (160)
- Rheumatoid arthritis (3258)
- Systemic lupus erythematosus (571)
- Degenerative joint disease (4641)
- Biological agents (545)
- Drugs: musculoskeletal and joint diseases (700)
- Epidemiology (1373)
- Pain (neurology) (883)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/